Jupiter Life Line Hospitals Stock: Analyst Bole 'BUY', Par Share Gira Neeche!

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorVihaan Mehta|Published at:
Jupiter Life Line Hospitals Stock: Analyst Bole 'BUY', Par Share Gira Neeche!
Overview

Bro, Jupiter Life Line Hospitals (JLHL) ka case thoda confusing hai. Ek taraf company ne Q3 mein **12%** YoY EBITDA growth dikhaya hai, jo expectations match karta hai. Lekin stock price seedha 52-week low ke aas paas ghoom raha hai, aur kuch analysts 'SELL' keh rahe hain, jabki Prabhudas Lilladher ne 'BUY' rating aur **₹1,600** ka target diya hai. Kya chal raha hai?

Analyst Bole 'BUY', Stock Bole 'SELL'?

Dekho, Jupiter Life Line Hospitals (JLHL) ke liye numbers toh theek-thak aa rahe hain. Q3 mein EBITDA 12% badhkar ₹850 million ho gaya, bilkul analysts ke prediction ke hisaab se. Company FY22 se FY25 tak revenue aur EBITDA mein 20% aur 25% ka CAGR maintain karne ki koshish mein hai [cite: Source A].

Isi performance par Prabhudas Lilladher ne bola hai ki bhai, 'BUY' karo, target ₹1,600 ka hai, jo FY28 ke EBITDA ka 23 guna hai [cite: Source A]. Lekin market mein ho kya raha hai? Stock price apni 52-week low ke paas ₹1,230 ke level par trade kar raha hai. Market cap bhi lagbhag ₹8,200 crore ke aas paas hai, aur P/E ratio 41.7-43.72 chal raha hai. Jabki competitors jaise Apollo Hospitals ka P/E 60.74 aur Max Healthcare ka 69.29 hai.

Expansion Plans Bade, Par Occupancy Ka Kya Scene?

JLHL apne business ko badhane ke liye kaafi aggressive plans bana raha hai. Agle 3-4 saal mein 6 naye greenfield hospitals kholne ka plan hai, jismein lagbhag 1,452 beds add honge, target hai total 2,500 beds network ka. February 2026 mein Dombivli hospital bhi start ho gaya hai.

Magar, existing hospitals ki occupancy rates thodi mixed hain. Thane mein 72.1%, Pune mein 54.9%, aur Indore mein 65.5%. Aur 9 mahine mein (Q3 FY26 tak) overall occupancy 560 basis points kam hokar 61.9% ho gayi thi. Iska reason naye beds add hona aur seasonal factors bataya ja raha hai. Upper se interest expenses aur medical inflation bhi pressure bana sakte hain.

Market Ka Mood Aur Analysts Ka Confusion

Broader market bhi JLHL ko lekar thoda confused lag raha hai. Kuch analysis platforms toh 'SELL' rating de rahe hain (jaise Mojo Score Feb 2026 mein), jo pehle 'Hold' tha. Yeh Prabhudas Lilladher ke 'BUY' call se bilkul alag hai, jinka target FY26-28E mein EBITDA aur PAT par 15% CAGR ka expectation hai [cite: Source A].

Overall Indian healthcare sector mein toh investment aa raha hai, bade players bhi beds badha rahe hain. Lekin JLHL ka stock Sensex aur sector ke peers se piche chal raha hai. Haalat yeh hai ki stock bade moving averages ke neeche hai. Ab dekho, company ka expansion plan toh accha hai, par short term mein occupancy badhana aur costs control karna bahut zaroori hai taaki yeh analyst targets justify ho saken.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.